| Literature DB >> 19701488 |
Juliet Addo1, Liam Smeeth, David A Leon.
Abstract
BACKGROUND: Low levels of detection, treatment and control of hypertension have repeatedly been reported from sub Saharan Africa, potentially increasing the likelihood of target organ damage.Entities:
Mesh:
Year: 2009 PMID: 19701488 PMCID: PMC2729720 DOI: 10.1371/journal.pone.0006672
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Flow diagram of study activities.
Baseline characteristics of study population.
| Participants | Non Participants | |||||
| Men (140) | Women (79) | All (219) | Men (55) | Women (33) | All (88) | |
| Mean age in years (SD) | 50.4 (6.8) | 50.4 (6.3) | 50.4 (6.6) | 48.0 (8.5) | 48.3 (6.2) | 48.1 (7.7) |
| Mean SBP in mmHg (SD) | 159.2 (19.6) | 151.7 (23.9) | 156.5 (21.5) | 158.6 (22.1) | 144.8 (20.6) | 153.4 (22.4) |
| Mean DBP in mmHg (SD) | 96.3 (11.4) | 92.7 (15.3) | 95.0 (13.0) | 97.2 (13.8) | 92.2 (11.5) | 95.3 (13.1) |
| Mean BMI in kg/m2 (SD) | 26.1 (4.5) | 29.9 (6.0) | 27.5 (5.4) | 25.1 (4.6) | 32.4 (5.6) | 27.9 (6.1) |
|
| ||||||
| Primary | 30.2 (42) | 29.1 (23) | 29.8 (65) | 40.0 (22) | 19.4 (28) | 32.6 (28) |
| Secondary | 25.9 (36) | 41.8 (33) | 31.7 (69) | 25.5 (14) | 58.1 (18) | 37.2 (32) |
| Tertiary | 43.9 (61) | 29.1 (23) | 38.5 (84) | 34.6 (19) | 22.6 (7) | 30.2 (26) |
|
| ||||||
| Never | 87.7 (121) | 98.7 (78) | 91.7 (199) | 78.2 (43) | 100 (33) | 86.4 (76) |
| Current | 6.5 (9) | 0 | 4.2 (9) | 12.7 (7) | 0 | 8.0 (7) |
| Ex-smoker | 5.8 (8) | 1.3 (1) | 4.2 (9) | 9.1 (5) | 0 | 5.7 (5) |
|
| ||||||
| Previously detected | 42.9 (60) | 72.2 (57) | 53.4 (117) | 43.6 (24) | 75.8 (25) | 55.7 (49) |
| Newly detected | 57.1 (80) | 27.9 (22) | 46.6 (102) | 56.4 (31) | 24.2 (8) | 44.3 (39) |
|
| ||||||
| No treatment | 76.4 (107) | 54.4 (43) | 68.5 (150) | 80.0 (44) | 51.5 (17) | 69.3 (61) |
| Current treatment | 23.6 (33) | 45.6 (36) | 31.5 (69) | 20.0 (11) | 48.5 (16) | 30.7 (27) |
|
| ||||||
| Duration reported% (n) | 42.9 (60) | 70.9 (56) | 53.0 (116) | 41.8 (23) | 72.7 (24) | 53.4 (47) |
| Mean duration in years (95% CI) | 5.3 (4.2–6.3) | 6.2 (4.5–7.9) | 5.7 (4.8–6.7) | 6.0 (3.4–8.6) | 6.7 (3.3–10.1) | 6.3 (4.3–8.4) |
|
| ||||||
| Controlled BP (<140/90 mmHg) | 3.6 (5) | 25.3 (20) | 11.4 (25) | 5.5 (3) | 33.3 (11) | 15.9 (14) |
| Grade 1 (mild) | 45.7 (64) | 36.7 (29) | 42.3 (93) | 45.5 (25) | 39.4 (13) | 43.2 (38) |
| Grade 2 (moderate) | 32.1 (45) | 19.0 (15) | 27.4 (60) | 21.8 (12) | 18.2 (6) | 20.5 (18) |
| Grade 3 (severe) | 18.6 (26) | 19.0 (15) | 18.7 (41) | 27.3 (15) | 9.1 (3) | 20.5 (18) |
|
| ||||||
| Controlled BP (<140/90 mmHg) | 15.2 (5) | 52.8 (19) | 34.8 (24) | 18.2 (2) | 50.0 (8) | 37.0 (10) |
| Grade 1 (mild) | 42.4 (14) | 27.8 (10) | 34.8 (24) | 45.5 (5) | 25.0 (4) | 33.3 (9) |
| Grade 2 (moderate) | 30.3 (10) | 8.3 (3) | 18.8 (13) | 9.1 (1) | 18.8 (3) | 14.8 (4) |
| Grade 3 (severe) | 12.1 (4) | 11.1 (4) | 11.6 (8) | 27.3 (3) | 6.3 (1) | 14.8 (4) |
Prevalence of hypertensive target organ damage among participants.
| CVD risk factor or complication | Definition | Number | Prevalence (%) |
| Retinopathy | No retinopathy | 62/209 | 29.8 |
| Grade 1 retinopathy | 118/209 | 56.5 | |
| Grade 2 retinopathy | 27/209 | 12.9 | |
| Grade 3 retinopathy | 2/209 | 1.0 | |
| Left ventricular hypertrophy on ECG | Positive | 70/210 | 33.3 |
| History of stroke | Positive | 6/217 | 2.8 |
| Proteinuria in the absence of nitrites and leucocytes | Negative | 169/217 | 77.8 |
| Trace | 19/217 | 8.8 | |
| Positive (>300 mg/day) | 29/217 | 13.4 | |
| Glomerular filtration rate | <60 ml.min−1per 1.73 m2 | 9/219 | 4.1 |
The number of participants was less than the total of 219 where some participants did not complete all investigations.
Association between hypertensive target organ damage and selected variables.
| Prevalence of any TOD% (n/N) | Model 1 OR (95% CI) | Model 2 OR (95% CI) | Model 3 OR (95% CI) | Model 4 OR (95% CI) | |
|
| |||||
| Male | 59.3 (70/118) | 1.00 | 1.00 | 1.00 | 1.00 |
| Female | 36.0 (27/75) | 0.39 (0.21–0.71) | 0.38 (0.20–0.71) | 0.32 (0.16–0.65) | 0.31 (0.15–0.66) |
|
| |||||
| 25–34 | 50.0 (3/6) | 1.00 | 1.00 | 1.00 | 1.00 |
| 35–44 | 58.6 (17/29) | 1.28 (0.21–7.86) | 1.20 (0.19–7.46) | 1.29 (0.20–8.26) | 1.18 (0.18–7.69) |
| 45–54 | 41.8 (41/98) | 0.65 (0.12–3.53) | 0.61 (0.11–3.37) | 0.65 (0.11–3.70) | 0.56 (0.10–3.31) |
| 55+ | 60.0 (36/60) | 1.32 (0.23–7.46) | 1.22 (0.21–6.99) | 1.39 (0.23–8.36) | 1.16 (0.18–7.42) |
|
| |||||
| Newly detected | 52.3 (46/88) | 1.00 | 1.00 | 1.00 | |
| Previously detected | 48.6 (51/105) | 1.31 (0.61–2.82) | 0.99 (0.42–2.29) | 0.99 (0.42–2.34) | |
|
| |||||
| No treatment | 53.0 (70/132) | 1.00 | 1.00 | 1.00 | |
| Current treatment | 44.3 (27/61) | 0.77 (0.35–1.73) | 1.04 (0.41–2.29) | 1.07 (0.42–2.74) | |
|
| |||||
| BP<140/90 | 34.8 (8/23) | 1.00 | 1.00 | ||
| SBP 140–159/DBP 90–99 | 42.5 (34/80) | 0.77 (0.24–2.52) | 0.84 (0.25–2.84) | ||
| SBP 160–179/DBP 100–109 | 47.2 (25/53) | 0.88 (0.25–3.05) | 0.96 (0.27–3.50) | ||
| SBP>180/DBP>110 | 81.1 (30/37) | 5.69 (1.46–22.07) | 6.14 (1.53–24.6) | ||
| p-trend | 0.001 | 0.001 | |||
|
| |||||
| Primary | 56.5 (35/62) | 1.00 | |||
| Secondary | 47.3 (26/55) | 1.05 (0.45–2.46) | |||
| Tertiary | 47.4 (36/76) | 0.83 (0.38–1.82) | |||
| p-trend | 0.62 | ||||
|
| |||||
| No diabetes | 49.7 (88/177) | 1.00 | |||
| diabetes | 56.3 (9/16) | 1.45 (0.44–4.78) | |||
|
| |||||
| No smoking | 49.2 (87/177) | 1.00 | |||
| Ex-smoker | 57.1 (4/7) | 1.08 (0.20–5.94) | |||
| Current smoker | 66.7 (6/9) | 1.11 (0.24–5.19) | |||
Only participants with no missing data were included in the models (N = 193).
Model 1 includes age and sex.
Model 2 includes age, sex, whether previously diagnosed with hypertension and whether on BP lowering treatment.
Model 3: includes age, sex, whether previously diagnosed with hypertension and whether on BP lowering treatment and BP level.
Model 4: includes age, sex, whether previously diagnosed with hypertension, whether on BP lowering treatment, BP level, education, smoking and diabetes.